Rubius Therapeutics, Inc. (RUBY) |
| 0.057 0.002 (2.7%) 12-29 15:49 |
| Open: | 0.0555 |
| High: | 0.057 |
| Low: | 0.055 |
| Volume: | 755,858 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 0.3763 |
| 52w Low: | 0.0032 |
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Sat, 30 Dec 2023
RUBY Price History for Rubius Therapeutics Stock - Barchart.com
Wed, 22 Feb 2023
Once high-flying Rubius to shut down. Its flameout is a lesson for biotech - STAT
Tue, 20 Dec 2022
Nolan succeeding Session as CEO of Taysha - BioCentury
Thu, 17 Nov 2022
Former Rubius CEO jumps to another Flagship spinout - The Business Journals
Mon, 07 Nov 2022
Softbank-backed Flagship startup lays off 65, replaces CEO - The Business Journals
Fri, 05 Aug 2022
Frank Zhang returns to Legend - BioCentury
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
